Neuroptika

Neuroptika is a clinical-stage biotechnology company developing novel regenerative and neuroprotective therapies for ophthalmic diseases, with a primary focus on retinal degeneration. The company's pipeline includes NRO-CMK targeting neurodegenerative glaucoma via AAV-delivered CaMKII gene therapy, NRO-VTN targeting drusen formation in dry AMD, and an undisclosed program for diabetic retinopathy. Neuroptika's approach addresses unmet needs in conditions affecting hundreds of millions of patients globally where current treatments cannot halt or reverse optic nerve and retinal damage. The company has completed Phase 2 clinical trials for its lead corneal nerve regeneration asset and holds exclusive licenses from Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys.